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Increased adiposity is a significant risk factor for many cancers, including breast cancer. 
Patients with breast cancer who are overweight or obese have an increased risk of recurrence, 
and breast cancer-related mortality. While several hypotheses have been proposed to explain 
the biological mechanisms that drive the obesity-breast cancer interconnections, progress in 
our understanding of the adipose tissue tumor microenvironment and its relevance to breast 
cancer initiation and progression or the emergence of resistance to therapy has been limited. 
In parallel to major breakthroughs on the increased adiposity as a risk and prognostic factor 
for several diseases and cancers, researchers have begun to utilize digital pathology to 
characterize the tumor microenvironment in diverse types of adipose tissue-rich neoplasia. 
Pioneering studies have uncovered the existence of a peculiar type of adipocytes named 
cancer-associated adipocytes in the microenvironment of tumors that grow in close contact 
with adipose tissue. At the time this thesis was started, only a few studies with small cohorts 
of patients and often, a limited number of adipocytes analyzed, mostly distant from the tumor, 
have shown the importance of the adipose tissue tumor microenvironment. However, an in-
depth knowledge was currently lacking for breast cancer. 
The work presented here harnesses the strength of digital pathology and state of the art of 
adipocyte measurement tools to analyze adipocytes in the adipose tissue microenvironment 
of breast cancer. Beyond providing histopathological criteria for adipocyte analysis, these 
results suggest that the analysis of mammary cancer-associated adipocytes is feasible using 
image analysis software. Moreover, our analyses reveal that cancer-associated adipocytes are 
smaller than distant adipocytes, reflecting the delipidation process undergone by cancer-
associated adipocytes. The body mass index of the patient is associated with the size of distant 
and cancer-associated adipocytes giving new insights in the evaluation of mammary adiposity 
of a patient. 
The data presented here are too preliminary to derive practice-changing evidence but provide 
the basis for performing adipocyte analysis on larger number of patients and support the 






L'obesità è un fattore di rischio significativo per molti tumori, compreso il carcinoma della 
mammella. I pazienti con carcinoma della mammella che sono sovrappeso o obesi hanno un 
aumentato rischio di recidiva e di mortalità correlata al tumore. Sebbene siano state proposte 
diverse ipotesi per descrivere i meccanismi biologici alla base dell’interazione tra obesità e 
carcinoma della mammella, i progressi nella comprensione del microambiente tumorale e del 
ruolo degli adipociti presenti in esso e della loro rilevanza per lo sviluppo e la progressione 
tumorale o per l'emergere di resistenze alle terapie sono ancora limitati. 
Parallelamente alle importanti scoperte sull'obesità come fattore di rischio e fattore 
prognostico per diverse malattie e tipi di tumore, i ricercatori hanno iniziato a utilizzare la 
patologia digitale per caratterizzare il microambiente tumorale. Studi pionieristici hanno 
scoperto l'esistenza di un tipo particolare di adipociti chiamati adipociti associati al tumore 
presenti nel microambiente di tumori che crescono a stretto contatto con il tessuto adiposo. 
Nel momento in cui è stata scritta questa tesi, solo pochi studi con piccole coorti di pazienti e 
spesso, un numero limitato di adipociti analizzati, per lo più distanti dal tumore, hanno 
mostrato la rilevanza del tessuto adiposo e degli adipociti come componente del 
microambiente tumorale. Tuttavia, allo stato attuale manca ancora una conoscenza 
approfondita del ruolo degli adipociti nel carcinoma della mammella. 
Lo studio presentato in questa tesi descrive le potenzialità della patologia digitale e fornisce 
una rappresentazione dello stato dell'arte sui software con algoritmi dedicati per la 
misurazione degli adipociti, con una attenzione per gli adipociti presenti nel microambiente di 
carcinomi mammari. Oltre a stabilire criteri istopatologici per l'analisi degli adipociti, i risultati 
presentati dimostrano che è possibile effettuare l'analisi degli adipociti associati al tumore 
come di quelli distanti, utilizzando un software di patologia digitale. Inoltre, abbiamo mostrato 
che gli adipociti associati al tumore sono più piccoli degli adipociti distanti, riflettendo il 
processo di delipidazione subito dagli stessi. Infine, l'indice di massa corporea del paziente è 
associato alle dimensioni degli adipociti distanti e associati al tumore, fornendo nuove 




I dati qui presentati, sono preliminari per un cambiamento diretto nella pratica clinica, ma 
forniscono i criteri per eseguire l'analisi degli adipociti su coorti più ampie di pazienti ed 
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Breast cancer incidence and current management: a short overview  
 
Breast cancer (BC) is the most commonly diagnosed cancer in Western Countries. To give an 
order of magnitude, in the European Union (EU), over 355,000 women are estimated to be 
diagnosed with BC in 2020[1]. BC also represents the first cause of cancer-related death in 
women with more than 90,000 deaths every year in the EU[2]. Mortality rates vary worldwide, 
and they have decreased in the last decades with the advent of more accurate prognostic 
predictors and with the introduction of novel treatments. Despite that, a considerable 
percentage of patients, between 20% and 30%, still fail to respond to treatments and die as a 
consequence of the development of distant metastases[3]. 
BC is a heterogenous disease with distinct clinical and molecular subtypes. The traditional BC 
management involves the evaluation of several clinico-pathological variables such as age, 
tumor size, axillary lymph node involvement, histopathological features (especially 
histological grade and lympho-vascular invasion) and key markers such as estrogen receptor 
(ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67. 
Taken together this information allows to identify three clinical phenotypes with different 
behaviors and treatment strategies: hormone receptor positive (HR+, ER+ and/or PR+), HER2 
positive (HER2+) and triple negative (TNBC: ER-, PR-, HER2-) BC. Patients with ER+ BC generally 
benefit from endocrine therapy. Similarly, patients with HER2+ BC may benefit from anti-HER2 
targeted therapy. Instead, the standard treatment for TNBC is based on chemotherapeutic 
agents. There are no targeted treatments available for this tumor type, at least in the early 
setting. There exist four molecular subtypes based on gene expression profile that partially 
overlap with the above-mentioned clinical subtypes: Luminal A, Luminal B, HER2+, and triple 
negative. This last molecular subtype, in turn, has been divided into seven molecular subtypes 
by Lehman and colleagues: immunomodulatory, mesenchymal, mesenchymal stem-like, 
luminal androgen receptor, unstable, basal-like 1 and basal-like 2 subtypes[4]. Thereafter, a 
refined sub-classification of the previous one was still proposed by Lehman and colleagues 
identifying 4 molecular subtype: basal-like 1, basal-like 2, luminal androgen receptor and 
mesenchymal[5]. These molecular subtypes differ with regard to their patterns of gene 
expression, clinical features, response to treatment, and prognosis[6–9]. In the last years, 
11 
 
prognostic tests based on multigene signatures such as MammaPrint® (Agendia) and the 
Oncotype DX® Breast Recurrence Score (Exact Sciences Corp.) have been introduced[10]. 
Large-scale studies have shown that these tests can potentially help to guide 
treatment[11,12]. 
BC not only consists of neoplastic cells, but also of significant alterations in the surrounding 
stroma or tumor microenvironment (TME). These alterations in various cells of the TME such 
as lymphocytes, fibroblasts, endothelial cells, adipocytes and other cells types, are now 
recognized as a critical element for BC development and progression, as well as potential 
therapeutic targets[13]. For instance, the evaluation of tumor infiltrating lymphocytes (TILs) 
in the TME has added important prognostic and predictive information to current BC 
management[14–16]. The recent introduction of immunotherapy, especially immune 
checkpoint inhibitors (ICIs), for the treatment of metastatic TNBC, has shown the important 
role of the TME in developing and modulating an anti-tumor response[17]. ICIs are novel 
agents that boost the immune system including the immune cells infiltrated in the TME[18,19]. 
Other cells present in the TME such as cancer-associated fibroblasts (CAFs), have been 
described in previous studies and are under investigation as potential target for cancer 
therapy[20]. More recently, adipocytes are gaining increasing attention due to the fact that 
they represent a major component of the TME in several types of cancer, specifically in BC. 
Also, the breast is a unique structure mostly composed of adipose tissue (AT) and adipocytes 
can interact with tumor cells and other cells from the TME[21]. The author will refer along the 
text to the white adipose tissue (WAT), without mentioning other types of AT, since WAT is 





The impact of obesity on breast cancer 
 
Obesity is a complex preventable disease and a global public health problem. Over a third of 
the world’s population is overweight or obese and a recent study estimated that by 2030 
nearly 1 in 2 adults will have obesity in the United States (US)[23,24] and 1 in 3 adults in the 
EU[25]. Moreover, obesity and even more severe obesity are more prevalent in women than 
men in the US[24]. Obesity is typically defined as an excessive fat accumulation and it is 
categorized according to the World Health Organization (WHO) criteria in terms of Body Mass 
Index (BMI, kg/m2). Overweight individuals have a BMI ranging from 25 to 29.9 kg/m2 and 
obese individuals have a BMI greater than or equal to 30 kg/m2[26]. Obesity is frequently 
subdivided into sub-categories with extreme or severe obesity defined by a BMI ≥ 40 
kg/m2[26] . 
Obesity is recognized as one of the major risk factors for several types of cancer, including BC, 
especially in the post-menopausal HR+ population[27,28]. The effect of obesity on BC risk 
differs according to menopausal status and disease subtypes. Several studies have shown a 
stronger association between increased BMI and a higher incidence of post-menopausal HR+ 
BC (33% increase of BC risk per 5 kg/m2 BMI increment) whereas the risk for post-menopausal 
ER- and TNBC seems to be minimally or inversely associated[29–31]. By contrast, an inverse 
association between obesity and pre-menopausal HR+ BC was observed (8-10% decrease of 
BC risk per 5 kg/m2 BMI increment) whereas pre-menopausal TNBC showed a higher BC 
risk[29,32,33]. Overweight and obesity not only impact the risk of developing BC, but also the 
prognosis and treatment efficacy of patients with BC. Obesity is a prognostic factor for worse 
clinical outcome independent from the menopausal status[34,35]. A large meta-analysis 
showed that obesity at the time of BC diagnosis was associated with an increased risk of total 
mortality and with an increased risk of BC mortality[36]. The increased mortality risk in obese 
women was mostly observed for HR+/luminal subtypes[37], while there are contrasting results 
regarding the increased mortality in TNBC obese women[38,39]. In contrast, a recent study 
showed that obesity was associated with worse prognosis in all molecular subtypes[40]. 
Furthermore, a few studies have shown that obesity was associated with an increased rate in 
distant, but not loco-regional recurrences[34,41]. A list of the most relevant studies evaluating 
the impact of the obesity on BC risk and prognosis is reported in Table 1. 
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Obesity also affects response to therapeutic treatments. Although some studies have shown 
that obese patients are often under treated due to the concerns about potential treatment 
toxicities[42], several pre-clinical studies have demonstrated that the TME can contribute to 
treatment resistance in obese patients[43–47]. A retrospective analysis of a large clinical trial 
showed that obese patients treated with taxane-based regimens had a worse outcome 
compared to lean patients, while no differences were observed in patients treated in the arms 
without taxanes[48]. Furthermore, another study showed that there might be a change in pCR 
rate according to BMI in patients with TNBC and high TILs levels treated with neoadjuvant 
chemotherapy. A higher pCR rate was observed in lean patients in comparison to 
overweight/obese patients[49]. Finally, there is some evidence that obesity might also affect 
endocrine therapy response. An exhaustive review of Jiralerspong and Goodwin summarized 
the main findings of several clinical trials showing a trend of less efficacy of anastrozole in 
post-menopausal overweight/obese women compared to lean women that it was not 
observed for letrozole[28]. 
Most of the studies that evaluated the links between obesity and BC risk/BC outcomes used 
BMI as main measure of patient’s adiposity. BMI is easy to measure, inexpensive, strongly 
correlated with body fat at population level and provides standardized definitions for lean, 
overweight and obese categories[50]. By contrast, it is considered a surrogate marker of 
adiposity because it does not reflect accurately the body composition of an individual, failing 
to distinguish between muscle mass and fat mass[51]. In addition, it does not consider fat 
localization, age and ethnic differences. For these reasons, the impact of patient’s adiposity 
on BC risk and BC outcomes might be greater. Complementary measures of assessment of 
body fat distribution have been evaluated and have gained interest in the last two decades: 
waist circumferences, waist to hip ratio, waist to height ratio, dual energy x-ray 
absorptiometry, bioelectric impedance, computerized tomography (CT) and magnetic 
resonance imaging (MRI)[52–54]. All these methods add specific information regarding body 
fat distribution compared to BMI, but they have some limitations such as the cost, the under 
or the overestimation of a specific fat depot, and the lack of standardization. A recent 
observational study showed that information on muscle quantity and adiposity from clinically 
acquired CT scans provide significant prognostic information that outperforms BMI[55]. CT 
and MRI are now considered to be the most accurate methods for measuring body 
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composition (fat and muscle mass), but their use is still limited to research purposes[56]. 
Lastly, it was observed, in several studies, that the size of the mammary adipocytes was 
strongly correlated with BMI[57–59]. Thus, histological measuring of adipocytes, might be a 
valid indicator of patient’s adiposity as well as giving information on health status and type of 
AT expansion. 
Overall, obesity has a significative impact not only on BC risk and mortality, but also on 
therapeutic management. To date, current BC treatments do not consider the patient’s 
adiposity. Therefore, there is an urgent need to find novel treatments and to optimize the 
existing treatments according to patient’s adiposity, together with more meaningful 
assessments of body (fat) composition at individual level. 
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 Author (year, journal) Study type and population Focus Results 
Obesity and BC risk     
 Park et al.[31] 
2020, Breast Cancer Res Treat 
1,418,180 premenopausal and 
4,854,187 postmenopausal  
Korean women.  
All BC subtypes 
To examine the association 
between obesity and BC  
 
In postmenopausal women, there was a 
positive association between obesity and BC 
risk (HR: 1.28, CI95%: 1.25 – 1.32). An inverse 
association was present between obesity 
and BC risk in premenopausal women (HR: 
0.95, CI95%: 0.91 – 0.98) 
 
 Pierobon et al.[33] 
2012, Breast Cancer Res Treat 
Meta-analysis of case-case and 
case-control studies  
24,479 BC  
3,845 TNBC  
To analyze the association 
between TNBC and obesity 
 
There was a greater risk in pre-menopausal 
women of developing a TNBC than non-
obese women (OR: 1.43, CI95%: 1.23 – 1.65) 
 
 Suzuki et al.[29] 
2009, Int J Cancer 
Meta-analysis of cohort and case 
control studies. Pre- and 
postmenopausal BC patients. 
All BC subtypes 
To clarify the association between 
BMI and the incidence of BC 
defined by ER/PR status of the 
tumors 
In premenopausal women there was a 20% 
lower risk for the development of ER+PR+ BC. 
In postmenopausal women there was 82% 
increased risk for ER+PR+ BC. Each increment 
in the BMI by 5 kg/m2 was associated with 
10% lower risk of premenopausal and 33% 
increased risk of postmenopausal BC 
 
 Renehan et al.[32] 
2008, The Lancet 
Meta-analysis of prospective studies 
of incidence cases of 20 cancer 
types 
23,909 postmenopausal BC women 
7,930 premenopausal BC women 
 
To determine the risk of cancer 
associated with a 5 kg/m² 
increase in BMI 
A 5 kg/m² increase in BMI was weaker 
associated with post-menopausal BC (RR: 
1.12, IC95%: 1.08 – 1.16) 
Obesity and BC prognosis     
 Lohmann et al.[40] 
2021, J Natl Cancer Inst 
Meta-analysis of 27 studies 
108,908 BC women 
All BC subtypes 
 
To evaluate the association of BMI 
with outcomes in non-metastatic 
BC across the spectrum of IHC 
defined BC subtypes (HR+HER2-, 




Obesity was associated with modestly worse 
DFS and OS in all BC subtypes.  
ER+/PgR+ HER2- (DFS, HR: 1.26, CI95: 1.13 – 
1.41; OS, HR: 1.39, CI95: 1.20 – 1.62) 
HER2+ Any ER/PgR (DFS, HR: 1.16, CI95: 1.06 – 
1.26; OS, HR: 1.18, CI95%: 1.05 – 1.33) 
TN (DFS, HR: 1.17, CI95%: 1.06 – 1.29; OS, HR: 




 Author (year, journal) Study type and population Focus Results 
Obesity and BC prognosis  
Pan et al.[37] 
2014, J Clin Oncol 
 
Meta-analysis of 21 pooled trials 
(EBCTCG data) 
80,000 BC women  
All BC subtypes 
 
To investigate the association 
between BMI and the risk of 
mortality 
 
BC specific mortality is worse in 
premenopausal obese patients with ER+ BC 
(RR: 1.34, CI95%: 1.22 – 1.4); no differences in 
postmenopausal patients 
 
 Chan et al.[36] 
2014, Ann Oncol 
Meta-analysis 
213,075 BC women 
All BC subtypes 
 
To explore the associations 
between BMI and the risk of total 
and cause-specific mortality, 
overall and in women with pre- 
and postmenopausal 
BC 
Obesity is associated with poorer OS in pre 
(RR: 1.75, CI95%: 1.26 – 2.41), and 
postmenopausal BC women (RR: 1.34, CI95%: 
1.18 – 1.53) and is associated with poorer BC 
survival (global RR: 1.35, CI95%: 1.24 – 1.47)  
 
 Ewertz et al.[34] 
2011, J Clin Oncol 
18,967 BC women (DBCG data), 
All BC subtypes 
To characterize the impact of 
obesity on the risk of BC 
recurrence and death 
The risk of developing distant metastases 
after 10 years was increased by 46% (HR: 
1.46, CI95%: 1.11 – 1.92), and the risk of dying 
as a result of BC after 30 years was increased 
by 38% for obese BC women (HR: 1.38, CI95%: 
1.11 – 1.71) 
 
 Protani et al.[35] 
2010, Breast Cancer Res Treat 
 
Meta-analysis 
Number of patients: not specified 
All BC subtypes 
 
To determine the effects of obesity 
on survival in newly diagnosed BC 
patients 
Obese BC women have a poorer OS and 
BCSS compared with non-obese women (HR: 
1.33, CI95%: 1.21 – 1.47), (HR: 1.33, CI95%: 
1.19 – 1.50) 
 
Table 1. Meta-analysis and national studies investigating obesity-breast cancer risk and obesity-breast cancer prognosis. 
The larger and most relevant studies are reported in the table. 
Abbreviations: BCSS, breast cancer–specific survival; BMI, body mass index; DBCG, Danish Breast Cancer Cooperative Group, EBCTG, Early Breast Cancer Trialists Collaborative Group; ER, 
estrogen receptor; HR, hazard ratio; IHC, immunohistochemically; RR, risk ratio; TN, triple-negative; OR, odds ratio; OS, overall survival
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Molecular mechanisms linking obesity to breast cancer 
 
The molecular mechanisms and the pathways involved in BC development and progression 
have not been fully elucidated yet in adipose-rich women. Several studies have hypothesized 
and described possible mechanisms[60–62]. Some of these mechanisms are shared by other 
cancer types and diseases linked to obesity. The main candidate mechanisms are discussed 
below, except for the role of TME and adipocytes in obesity-associated chronic inflammation 
that will be discussed in a separate paragraph.  
Estrogens. 17-b-estradiol (E2) and estrone (E1) are the two main estrogens produced in pre-
menopausal and post-menopausal women. Aromatase is the key enzyme presents in AT, that 
mediates the conversion of androgens to estrogens and its activity is higher in the expanded 
AT of obese women[63]. AT contributes up to 100% of circulating estrogens in post-
menopausal women whereas the ovaries are the major source of estrogens  in pre-
menopausal women[64]. Estrogens are one of the major factors for post-menopausal ER+ BC 
risk. In particular, a recent study showed for the first time how E2 and E1 act in pre and post-
menopause. The pro-inflammatory effect of higher levels of E1 that occur in post-menopausal 
and obese women are unopposed by the anti-inflammatory effects of E2, predominant in pre-
menopausal women[65]. Therefore, the declining E2:E1 ratio after menopause and the 
increased inflammatory cytokine environment, in obesity, might in part explain why obese 
women are exposed to an increased risk of developing ER+ BC after menopause and not 
before. Another hypothesis is that obese women have a significant disruption in the menstrual 
cell cycle resulting in less exposure to estrogens than normal weight women, therefore leading 
to a decreased ER+ BC risk[66,67]. 
Adipokines. Adiponectin and leptin are the two major adipokines secreted by adipocytes. In 
normal condition, they contribute to maintain a metabolic homeostasis. In obese individuals, 
metabolic homeostasis is commonly disrupted with an increase of leptin, not counterbalanced 
by an increase of adiponectin[68]. Adiponectin is protective against cancer, having anti-
inflammatory, anti-proliferative, insulin-sensitizing properties and promoting a healthy AT 
expansion[61,68]. By contrast, leptin whose levels are correlated to the fat mass, activates 
several signaling pathways such as JAK/STAT, MAPK/ERK, and PI3K/AKT involved in tumor 
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development and progression[69]. In addition, leptin, at high concentration, can increase 
aromatase activity fostering higher level of estrogens in obese women[70]. 
Insulin-like growth factor (IGF-1) pathway. Several metabolic pathways are dysregulated in 
obese women. In particular the IGF-1/IGF-1R pathway seems to be one of the most relevant 
in contributing to breast carcinogenesis[71]. IGF-1 levels are increased in obese women as a 
consequence of hyperinsulinemia, a common condition in obese women affected by 
metabolic syndrome[72]. Moreover, IGF-1 is tightly linked to ER increasing the transcriptional 
activity of ER and it also can act in synergy with estradiol inducing a mitogenic response in 
breast epithelial cells[73]. A recent study has not only shown that there was an association 
between higher levels of IGF-1 and BC development, but also, that IGF-1 was likely to be a 
cause of the disease[74]. 
Metabolic Inflammation. Most obese women present with a systemic and chronic low-grade 
inflammation termed metabolic inflammation. Obese MAT is characterized by several 
immune-metabolic changes including hypertrophy of adipocytes and the presence of crown-
like structures (CLS)[75]. CLS are defined by the presence of CD68+ macrophages surrounding 
necrotic adipocytes. CLS are considered as a histologic marker of AT inflammation and are 
associated with obesity, post-menopausal status[76], aromatase activity[77,78] and insulin 
resistance[79]. The incidence of CLS in BC patients is ~50% and it is higher in overweight and 
obese women with an incidence of 53-70% and 75%-90%, respectively[75,76,80]. Of interest, 
the presence of CLS has been described in a not negligible percentage, around 34-39%, of lean 
women defined as metabolically-obese normal-weight women[76,78]. Furthermore, a study 
showed that the presence of CLS was higher in patients who received neoadjuvant 
chemotherapy compared to patients who did not receive neoadjuvant chemotherapy[76]. 
Most of the studies evaluated CLS on mastectomy specimens of BC patients[76,81]. On the 
contrary, Vaysse et al, evaluated CLS on both lumpectomy and mastectomy specimens, and 
found CLS, mainly in overweight/obese women with low grade tumors treated with breast 
conservative surgery[58]. Overall, the presence of CLS in MAT may contribute to generate a 
pro-inflammatory environment favorable to BC initiation and progression. Moreover, the 
hypoxia in expanding MAT may trigger inflammatory responses[82], suppressing the synthesis 
of anti-inflammatory adipokines such as adiponectin[83] and increasing the synthesis of pro-
inflammatory cytokines such as interleukin-6 (IL-6)[84]. Iyengar and colleagues reported that 
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MAT inflammation was associated with short overall survival and short recurrence-free 
survival in BC[79]. A recent study showed that the presence of free fatty acids (FFAs), often 
elevated in the blood of obese women, increased the risk of ER+ BC in the obese 
postmenopausal population through ERα and mTOR signaling pathways[85]. 
Overall, the local and systemic alterations induced by obesity may influence BC development 
and progression through direct effects on cancer epithelial cells as well as indirect effects on 
the TME.   
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Obesity and tumor microenvironment  
 
The TME influences cancer development and progression through a bidirectional and dynamic 
crosstalk between cells constituting the TME and cancer cells. Mammary TME consists of 1) a 
cellular compartment including cancer cells, adipocytes, fibroblasts, immune cells such as 
macrophages and lymphocytes, endothelial cells, pericytes, and, 2) a non-cellular 
compartment mainly constituted of extracellular matrix (ECM)[86]. Adipocytes are a key 
player orchestrating local changes in the TME of BC and they will be discussed in a separated 
paragraph. The other main players are the following: 
Tumor-associated macrophages (TAMs). TME defines remodeling of both infiltrating and 
resident macrophages into TAMs. Up to 90% of macrophages in obese TME are associated 
with adipocytes hypertrophy and adipocytes necrosis[87,88]. There are two main classically-
described phenotypes of macrophage activation: M1 and M2[89]. M1 macrophages respond 
to a series of stimuli including tumor necrosis factor alpha (TNF-α) and interferon gamma (INF-
γ) secreting specific molecules with pro-inflammatory properties, anti-cancer activity and 
associated to insulin resistance. Instead, M2 macrophages have different surface markers and 
respond to another spectrum of stimuli such as IL-4 and IL-10 resulting in anti-inflammatory 
activity, immune tolerance, insulin sensitivity and promoting tumor development and 
progression [72]. Besides the classical model of M1/M2 macrophage activation, recent studies 
have revealed a more complex range of macrophage activation states, and the existence of 
different macrophage profiles based on BMI, location of AT depots and between non-cancer 
and cancer patients[49,90]. For instance, subcutaneous adipose tissue (SAT) of obese 
individuals exhibits a mixed phenotype characterized by the simultaneous presence of 
markers that generally belong to M2‐ and M1‐ macrophages [91]. Another study showed that 
obese MAT of non-cancer patients had an increased density of M2-biased or TAM-like 
macrophages promoted by the remodeling of ECM that occurs in obese individuals[92]. 
Moreover, Tiwari and colleagues, showed that in MAT of obese TNBC patients, the 
predominant macrophages phenotype was composed by a mixed phenotype with pro-




Tumor-infiltrating lymphocytes (TILs). A subpopulation of BC is able to mount an anti-tumor 
immune response. One of the discriminant features is the ability of T lymphocytes to infiltrate 
the tumor. TILs of the stromal compartment are generally quantified on hematoxylin-eosin 
(H&E) stained slides, and the result is a continuous variable expressed as percentage of the 
stromal surface area occupied by TILs[16,94]. TILs were more frequently observed in high-
grade lesions, in TNBC and HER2+ BC[95,96]. A low TILs infiltrate has been associated with poor 
outcome in TNBC patients[96,97]. A large pooled analysis has demonstrated that higher levels 
of TILs predict pathological complete response (pCR) to neoadjuvant chemotherapy in 
patients from all molecular subtypes, but longer survival only in TNBC and HER2+ BC[95]. In 
addition, a recent study showed that a subgroup of systemically untreated patients with early 
stage TNBC having an excellent prognosis was identified by a TILs cut-off of 30%[98]. In 
consideration of the consistent findings, TILs have now been integrated in the new WHO 
classification of breast tumors[99]. Furthermore, recent experimental and human data have 
revealed that the adiposity of a subject can influence the TME inducing T-cell 
dysfunction[100].  
Cancer-associated fibroblasts (CAFs). Fibroblasts are one of the most abundant cell types in 
tumor stroma and they can become CAFs in the TME. CAFs residing in the TME are 
heterogeneous cells with different functions (pro or anti-tumor activities) and different 
surface markers. CAFs can originate from a wide range of cells including CAAs and adipose-
derived stromal/stem cells (ASCs), especially in obese patients[101]. CAFs are the major 
contributor to the remodeling and to the stiffness of ECM observed in tumors[20]. CAFs 
positively influence the proliferation and metabolism of cancer cells through oxidative stress. 
CAFs promote angiogenesis, tumor initiation and tumor progression[20,102]. Furthermore, 
Costa and colleagues identified four CAF subpopulations, according to the expression levels of 
specific fibroblast markers in a series of BC. They discovered as one of these CAF 
subpopulations named CAF-S1 might be involved in creating an immunosuppressive 
environment in BC[103]. Another work showed that some CAFs subpopulations may induce 




Mammary adipose tissue and adipocytes  
 
Adipose tissue is no longer seen as a mere energy depot. It has been recognized to be involved 
in various biological processes including energy metabolism, neuroendocrine function and 
immune function. In general, in obese individuals, there is a pathological expansion of WAT 
that occurs mainly in response to overnutrition. AT presents a considerable heterogeneity 
across fat depots consisting in different anatomic locations and distinct functions[22]. SAT, the 
largest fat depot present in the body, and visceral adipose tissue (VAT) are the most well 
characterized fat depots with regard to the mechanisms of expansion (hypertrophy vs. 
hyperplasia) and the contribution to metabolic disease. 
Mammary adipose tissue is a specialized fat depot that can represent up to 56% of the volume 
of the non-lactating breast tissue and 35% of lactating breast tissue[105]. It is constituted by 
adipocytes, the most abundant cell type, and by a stroma-vascular fraction that includes 
immune cells, fibroblasts, pericytes, endothelial cells, ECM, precursor of adipose cells (pre-
adipocytes and ASCs), and nerve fibers[106]. MAT undergoes physiological remodeling in the 
context of pregnancy, lactation, post-lactation involution and age-related involution[22,107]. 
It can also undergo pathological remodeling: in obesity, where MAT becomes dysfunctional 
and does not expand properly to store the energy excess, and in BC initiation and progression 
where adipocytes become able to communicate with cancer cells and turn into the so-called 
cancer-associated adipocytes (CAAs), establishing a bidirectional cross-talk with cancer 
cells[108]. Although it is still under investigation, an interaction between adipocytes and 
cancer cells might already occurs at pre-invasive stage of BC as it has been hypothesized that 
the breast-associated adipocytes secretome of obese individuals might be conducive to tumor 
development and progression[109,110]. In a recent work, we showed the association 
between adipocyte size and the risk of a subsequent ipsilateral invasive BC after primary DCIS 
supporting the role of adipocytes in promoting BC[111]. 
Initially, adipocytes are separated from the normal mammary epithelium by a fibrous layer 
that during tumor initiation is disrupted bringing the adipocytes in direct contact with cancer 
cells. The invasive front (IF) of the tumor is a crucial region where adipocytes engage cancer 
cells in a direct interaction. CAAs located at the IF are defined as peritumoral (Fig. 1) whereas 




Figure 1. Adipocytes located at the invasive front of the tumor. 
H&E slide scanned at 40x magnification. 
 
Figure 2. Adipocytes located at a distance > 2 mm from the tumor. 
H&E slide scanned at 40x magnification. 
CAAs have distinct phenotypes with respect to their normal counterpart that generally is at a 
certain distance from the tumor(Fig. 2). CAAs are smaller, with smaller lipid droplets, aberrant 
secretion of inflammatory cytokines such as TNF-α, IL-6 and IL-1β as well as proteins involved 
in ECM remodeling like matrix metalloproteinase 11(MP11)[113]. The hallmark of CAAs is the 
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delipidation, a process that through the release of FFAs fuels cancer cells growth. Cancer cells, 
in turn, undergo a metabolic reprogramming with a dramatically increased of use of lipids 
[114]. In addition, the metabolic symbiosis between adipocytes and cancer cells enhances 
both ketogenesis in adipocytes and ketolytic activity in BC cells[115]. Ultimately, CAAs may 
acquire a fibroblast-like phenotype with migratory and invasive abilities and complete 
disappearance of adipocyte markers contributing to the so-called desmoplastic reaction – 
dense fibrous tissue surrounding the tumor[116]. The transfer of FFAs to cancer cells occurs 
through three main proteins: CD36 [fatty acid translocase (FAT)], fatty acid binding protein 3 
(FABP3) and fatty acid binding protein4 (FABP4)[71]. FFAs can be used by cancer cells as 
building blocks for newly synthetized membrane phospholipids[117]. In obesity, the CAAs-
cancer cells cross-talk might be amplified, as it was observed that CAAs seem to be more prone 
to release lipids to cancer cells[114]. Moreover, the amount of lipid transfer might be different 
according to the tumor subtype, as a recent in vitro study showed that TNBC cell lines had the 
highest lipid transfer[118]. CAAs has been described to influence BC therapy response through 
several mechanisms. For example, major vault protein (MVP) is a transport-associated protein 
present in cancer cells, whose expression is upregulated by adipocytes, especially in obese 
individuals, and promotes chemotherapy resistance[44]. AT hypoxia is another mechanism of 
resistance to chemotherapy and also to anti-angiogenic drugs[47,112]. Furthermore, CAAs 
might promote a radioresistant phenotype in BC cells through the enhancement of IL-6 
expression[119]. 
Collectively, all these findings suggest an important role for CAAs in BC evolution and response 




State of the art in adipocytes measurements  
 
Adipose tissue homeostasis is orchestrated in part by the balance between adipocyte 
hypertrophy and pre-adipocyte hyperplasia. Both hypertrophy and hyperplasia are related to 
AT expansion and are known to be involved in a wide range of diseases including several types 
of cancer[109,120]. Therefore, determining the changes in AT volume deriving from 
hypertrophic or hyperplastic adipocytes, along with the specific location of AT growth, is 
important to understand the mechanisms driving obesity and cancer. Since the present work 
focuses on adipocytes measurements in MAT of BC, an overview of the available techniques 
for counting and measuring adipocytes in AT samples will first be provided. 
Microscopic measurements on conventional histological preparations or fresh-cut AT, 
automatic counting or sizing of osmium tetroxide-fixed fat cells or collagenase-isolated 
unfixed adipocytes in a suspension using a Coulter electronic counter are some of the methods 
that have been described[121–126]. Although no gold standard technique exists for adipocyte 
counting and size measurements, manual count and manual tracing of cross-sectional area 
are considered the reference techniques[127]. The major limitation is that these procedures 
are tedious and extremely time-consuming if performed on a large number of adipocytes. 
Therefore, several image analysis software have been developed for counting and measuring 
adipocytes in an automated way. These software rely mainly on histological images. Others 
automated image analysis tools use cell suspension but the major limitations are the 
complexity in preparing the suspension and the complete loss of the histopathological 
context. Instead, one of the advantages of using histological samples is the preservation of AT 
architecture that is crucial to study the AT TME in cancer and other diseases. In addition, 
preparation of histological samples have a low cost and histological samples are available for 
retrospective analysis and other types of analysis such as immunohistochemical staining. On 
the other hand, some of the possible limitations are the poor fixation and the damaged AT 




Figure 3. Example of damaged adipose tissue not suitable for adipocyte analysis. 
H&E slide scanned at 40x magnification. 
There exist open-source software dedicated to adipocyte analysis such as AdipoCount[129], 
Adiposoft[127] developed as a plug-in for ImageJ[130], QuPath[131] and others, or 
proprietary software including HALO® (Indica Labs, Corrales, US) and VisioPharm® (Hørsholm, 
DK). All these software or at least their modules/plug-ins, are built for adipocyte analysis and 
the majority has been tested on AT of non-cancer patients or obese individuals where the AT 
is more regular. Few studies tested these software in cancer patients in whom the remodeling 
of AT driven by cancer is extremely higher and disordered, and adipocytes are intermixed to 
cancer cells and other cell types. Moreover, most of these studies focused on adipocytes 
located far from the IF of the tumor. The studies that evaluated adipocyte size in MAT of BC 
patients are listed in Table 1. Most of the studies are performed on a limited number of 
adipocytes (~30) due to the inherent limitation of the manual analysis and on adipocytes 
distant from the tumor. The work of Vaysse et colleagues is the first in the BC field that used 
an automated software algorithm on a large number of adipocytes[58].  
Overall, there is a lack of standardization for measuring adipocytes and a lack of criteria for 
the histopathological identification of CAAs in BC patients.  
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Greenlee et al.[132] 
2019, Cancer Prev Res 
Hispanic/Latin women (n = 137) 
Breast WAT (distant) 
Linear Dimensional Tool in Canvas 11 
(ACS Systems of America, Inc.) 
30 or more adipocytes per patient 
Association of breast WAT 
inflammation with 




WAT inflammation was associated 
with BMI, adipocyte size, smoking 
history and neoadjuvant 
chemotherapy, ALT 
Iyengar et al.[80] 
2018, Cancer Prev Res 
Taiwanese women (n = 72) 
Caucasian women (n = 237) 
Breast WAT (distant) 
Linear Dimensional Tool in Canvas 11 
(ACS Systems of America, Inc.) 
30 or more adipocytes per patient 
Association of breast WAT 
inflammation with 
adipocyte size, body 
composition and serum 
markers 
WAT inflammation in Taiwanese 
women was associated with BMI, 
adipocyte size, CRP. triglycerides, 
insulin. Taiwanese women have 
larger breast adipocytes and lower 
BMI on average than Caucasian 
women 
 
Vaysse et al.[58] 
2017, NPJ Breast Cancer 
Women (n = 107) 
Breast WAT (distant) 
Adiposoft 
~ 300 adipocytes per patient 
Association of breast WAT 
inflammation with 
adipocyte size, body 
composition and serum 
markers 
 
WAT inflammation correlated with 
BMI, adipocyte size, CRP (pre-
menopausal), triglycerides (post-
menopausal) 
Iyengar et al.[78] 
2017, Cancer Prev Res 
Normal weight women (n = 72) 
Breast WAT (distant) 
Linear Dimensional Tool in Canvas 11 
(ACS Systems of America, Inc.) 
30 or more adipocytes per patient 
Association of breast WAT 
inflammation with 




WAT inflammation correlated with 
aromatase activity, adipocyte size, 
leptin, insulin, triglycerides 
Dobbs et al.[126] 
2016, Int J Cancer 
Women (n = 22) 
Breast WAT (distant and adjacent to BC) 
Confocal fluorescence microscopy 
and in-house computerized algorithm 
in MATLABVR ® (R2011b, 
MathWorksV®). Number of 
adipocytes: not specified 
Assessing whether confocal 
microscopy can identify 
changes in adipocyte 
morphology and size near 
the margins of BC 
and pre-invasive lesions 
Adipocytes adjacent to tumor 
margins are smaller in area 
compared to adipocytes far from 
the margins of BC and compared 










Iyengar et al.[76] 
2015, Cancer Prev Res 
Women (n = 237) 
Breast WAT (distant) 
Linear Dimensional Tool in Canvas 11 
(ACS Systems of America, Inc.) 
30 or more adipocytes per patient 
 
Association of breast WAT 
inflammation 
with BMI and menopause 
WAT inflammation was 
significantly associated with 
menopausal status and BMI 
Morris et al.[63] 
2011, Cancer Prev Res 
Obese women (n = 30) 
Breast WAT (distant) 
Linear Dimensional Tool in Canvas 11 
(ACS Systems of America, Inc.) 





The severity of breast 
inflammation correlated with both 
BMI and adipocyte size 
Table 2. Clinical studies evaluating adipocytes in breast cancer patients. 




Aims and Objectives 
 
The previous paragraphs summarized the major findings of the most influential studies which 
have shaped our understanding of the association of BC and obesity from different 
perspectives.  
In line with the above, the overarching goal of the present research is the application of digital 
pathology to quantify mammary adiposity in the context of BC by focusing on the most 
abundant cell type of the adipose tissue, the adipocytes.  
 
The present work was a pilot study to evaluate the feasibility of using digital pathology to 
measure adipocytes in H&E stained slides of breast tumour and to define criteria for 
subsequent analyses. We conducted our analysis on ten patients from a cohort of 66 post-
menopausal ER+ BC patients. At the time this work was completed, the analysis of the entire 
cohort was ongoing. Furthermore, several translational clinical trials developed from our 
group that were starting to enroll patients or that were in the last phase of approval, will use 
the adipocyte analysis developed in this work. 
 
Our aims and objectives were as follows: 
 
1. To test the accuracy of multiple software of digital analysis in order to identify the most 
suitable software tools for adipocyte analysis in BC. 
2. To develop histopathological criteria for the recognition of distant and CAAs.  
3. To evaluate possible associations between distant and CAAs and patient’s adiposity 
measured as BMI.  
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Adipocytes and cancer-associated adipocytes (CAAs) are poorly investigated cells in the tumor 
microenvironment. Different image analysis software exist for identifying and measuring 
these cells using scanned hematoxylin and eosin (H&E)-stained slides. It is however unclear 
which one is the most appropriate for breast cancer (BC) samples. Here, we compared three 
software (AdipoCount, Adiposoft, and HALO®). HALO® outperformed the other methods with 
regard to adipocyte identification, (> 96% sensitivity and specificity). All software performed 
equally good with regard to area and diameter measurement (concordance correlation 
coefficients > 0.97 and > 0.96, respectively). We then analyzed a series of ten BC samples (n = 
51 H&E slides) with HALO®. Distant adipocytes were defined as >2 mm away from cancer cells 
or fibrotic region, whereas CAAs as the first three lines of adipocytes close to the invasive 
front. Intra-mammary heterogeneity was limited, implying that measuring a single region of 
∼500 adipocytes provides a reliable estimation of the distribution of their size features. CAAs 
had smaller areas (median fold-change: 2.62) and diameters (median fold-change: 1.64) as 
compared to distant adipocytes in the same breast (both p = 0.002). The size of CAAs and 
distant adipocytes was associated with the body mass index (BMI) of the patient (area: rho = 
0.89, p = 0.001; rho = 0.71, p = 0.027, diameter: rho = 0.87 p = 0.002; rho = 0.65 p = 0.049, 
respectively). To conclude, we demonstrate that quantifying adipocytes in BC sections is 
feasible by digital pathology using H&E sections, setting the basis for a standardized analysis 
of mammary adiposity in larger series of patients. 
Introduction 
Mammary adipose tissue (MAT) represents up to 56 percent of the total breast 
volume[134] and it is composed of different cell populations such as endothelial cells, 
fibroblasts, immune cells, pericytes, various stem and progenitor cells in addition to 
adipocytes[109]. Adipocytes are normally separated from the human mammary epithelium 
by a layer of specialized stroma in which the terminal ductal lobular units are embedded. This 
layer is disrupted during tumor initiation/growth, bringing the adipocytes in close contact with 
BC cells[87]. The so-called cancer-associated adipocytes (CAAs) have unique characteristics as 
compared to mature adipocytes: they are characterized by fibroblast-like phenotypes, smaller 
size, reduced lipid content, free fatty acids release and immunomodulatory adipokine 
secretion[21]. Cancer cells can induce the delipidation of CAAs[70] and undergo a metabolic 
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reprogramming with a shift from oxidative to lipid metabolism. The two main subpopulations 
of CAAs are peritumoral adipocytes that are located at the invasive front of the tumor and 
intratumoral adipocytes that infiltrate into or are engulfed by the tumor[112]. CAAs can also 
cause resistance to radiotherapy[112] and to chemotherapeutic drugs through different 
mechanisms[44,135]. All these complex interactions between CAAs and cancer cells seem to 
be more pronounced in obese patients[87,136].  
Obesity has been become increasingly prevalent in most parts of the world over the 
last decades[137]. Recent projections estimate that nearly 1 in 2 adults will probably be obese 
by 2030 in the US, and this proportion will even be more accentuated in women[23]. Obese 
patients mostly have a global dysfunctional state mainly characterized by metabolic and 
immunologic alterations. This leads to an increased risk for developing various cancers among 
which BC, especially estrogen receptor (ER)-positive BC in the post-menopausal 
population[65,138]. Additionally, obesity has been shown to negatively impact the prognosis 
of BC patients[28,36]. Iyengar and colleagues have observed that the majority of the obese BC 
patients have a chronic inflammatory state in the MAT[76]. This is characterized by the 
hypertrophy of adipocytes, the formation of Crown-Like Structures (CLS), which are dying or 
dead adipocytes surrounded by macrophages, elevated levels of the aromatase enzyme[78], 
and the presence of inflammatory cytokines such as IL-6[58]. Inflammation of the MAT could 
still be further modulated by physical activity, diet and drugs although data are limited so 
far[117,139]. Recently, Iyengar et al. demonstrated that even a subgroup of lean patients can 
present a status of chronic inflammation associated with the MAT[78], emphasizing the 
limitation of BMI to accurately capture patient’s and mammary adiposity. Tools and methods 
are therefore needed to correctly identify and measure adipocytes and CAAs in order to 
quantify and characterize mammary adiposity. Intra-mammary comparison of the size of 
distant adipocytes and CAAs could further be used to quantify the magnitude of adipocyte 
delipidation. 
So far, most studies that aimed to measure mammary adipocytes only considered the 
largest diameter of a relatively small number of carefully selected adipocytes distant from the 
tumor, without considering CAAs[58,75,76,78,140]. Acknowledging the limitation in the 
number of evaluable adipocytes with this manual/semimanual methods, several image 
analysis software have been developed to automize this process. An important challenge for 
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these software is to analyze CAAs, since they are close to or inter-mixed with other cell types. 
So far, extensive intra-mammary comparative studies between distant and CAAs using digital 
pathology have to the best of our knowledge not been performed yet.  
In this study, we first compared the characteristics and outputs of three main image 
analysis software for identifying and measuring adipocytes (AdipoCount[129], Adiposoft[127], 
and HALO®). Then, using the best platform, we analyzed a series of BC tissues to measure 
distant adipocytes and CAAs and their potential association with the body mass index (BMI) 
of the patient.  
Materials and Methods 
Patients and slides 
We selected a total of 51 H&E slides from ten BC patients treated at the Institut Jules 
Bordet (Brussels, Belgium). The selection criteria were the following: 1) postmenopausal 
status of the patient at diagnosis, 2) estrogen receptor (ER)-positive status of the tumor, 3) 
availability of multiple (at least 2) formalin-fixed paraffin-embedded blocks from primary 
surgery with distant adipocytes and CAAs, and 4) availability of BMI status of the patient 
recorded on the day of oncological surgery. BMI (kg/m2) was categorized according to WHO 
criteria[26]. We considered only post-menopausal BC ER+ starting from the evidence that 
obesity is more prevalent in post-menopausal women and the link obesity-BC seems to be 
tighter in this population. All patients selected had an invasive breast carcinoma, five patients 
had an invasive breast carcinoma of no special type, commonly referred to as invasive ductal 
carcinoma, and five patients had an invasive lobular carcinoma. Eight patients had T2 stage at 
diagnosis and two patients T3. All the patients were treated with neoadjuvant endocrine 
therapy with letrozole followed by surgery. The age of the patients ranged from 58 to 82 years, 
with a mean 70.3 years. For nine patients, there were at least three evaluable slides with CAAs 
and distant adipocytes, and for one patient there were only two. For the first part of the study, 
we selected an area comprising ~ 100 adipocytes in three test H&E slides taken from this 
cohort, to compare the three software. For the second part of the study, we analyzed ~500 
distant and ~500 CAAs in multiples slides per patient for 10 patients to assess intra-patient 
and inter-patient heterogeneity (see power calculations in Supplementary Methods). The 




Digital Pathology and software analysis 
H&E stained tissue slides were scanned using a Nanozoomer digital slide scanner 
(c10730-12, Hamamatsu) with a 40x objective (0.228 μm/pixel). For the software comparison, 
the test slides were imported as PNG images into AdipoCount, Adiposoft version 1.16 and 
HALO® version 2.3 (Vacuole module, Indica Labs, Corrales, CA). We compared the correct 
identification of adipocytes, considering visual identification as the gold standard, their areas 
and diameters. Computation of the area was based on the number of pixels in the object for 
the three software. The area-output unit was μm² for Adiposoft and HALO® and pixels for 
AdipoCount. We therefore converted pixels in μm² multiplying the area in pixels obtained for 
each object with the area of one pixel in µm². Diameter-output unit was μm for Adiposoft and 
HALO®. AdipoCount did not provide the diameter. In HALO®, an algorithm estimates the 
centroid of the object, records 18 diameters passing through the centroid of the object at 
different angles, and then consider the median of those 18 diameters as the final measure. In 
the current version of Adiposoft, the diameter is an equivalent diameter that assumes 
roundness of the objects. For the second part of the project, all digital slides were imported 
as NDPI images into HALO® software for subsequent steps, including annotation, 
segmentation, count and measurements of area and diameter of adipocytes. We extracted 
the area and diameter of each single adipocyte for each annotated region. We did not include 
adipocytes with a diameter < 30 µm to exclude artefacts[76]. Based on microscopic evidence 
and literature[126], we defined adipocytes distant from the tumor as those being at least 2 
mm away from cancer cells as well as 2 mm away from fibrosis area and epithelial structures. 
CAAs were defined as the three first lines of adipocytes at the invasive front of the tumor, 
which are mostly in contact with invasive tumor cells (peri-tumoral CAAs), and as maximum 2 
mm within the tumor starting from the invasive front (intra-tumoral CAAs). These criteria were 
established by an expert breast pathologist (D.L). The areas to be analyzed were drawn by E.I. 
under the supervision of two breast pathologists, D.L. and M.D.S., according to the 
aforementioned criteria. We manually excluded adipocytes with incomplete stain of the 





Sensitivity (SS) and specificity (SP) of adipocyte identification were evaluated for each 
software. For the computation of SS and SP, we considered as true positives (TP), the 
adipocytes previously manually identified that software recognized correctly. False positives 
(FP) were fragments of cells or white areas that software recognized incorrectly as adipocytes. 
True negatives (TN) were fragmented cells or white areas that software did not recognize as 
adipocytes. False negatives (FN) were manually identified adipocytes that the software did not 
recognized as such. SS and SP were calculated as TP/(TP+FN) and TN/(TN+FP), respectively. 
The agreements regarding diameter and area were assessed using the Bland–Altman method, 
Passing–Bablok regression[141] and concordance correlation analyses. Bland–Altman plots 
represent the difference of the areas and diameters computed by each software plotted in a 
head-to-head comparison. In the Passing–Bablok regression lines, intercepts and slopes 
indicate constant and proportional bias respectively. Associations between continuous and 
(ordinal) categorical variables were assessed using Wilcoxon and Mann-Kendall tests. 
Association between adipocyte count and BMI was assessed using Mann-Kendall’s tau 
coefficient when BMI was considered as a categorical variable whereas Spearman correlation 
coefficient was used when BMI was considered as a continuous variable. McNemar's Chi-
squared test was used to assess the statistical difference between HALO® and the two other 
software concerning sensitivity and specificity. Statistical analyses were performed using R 
version 3.5.2. 
Results  
Comparative analysis of HALO®, Adiposoft and AdipoCount for adipocyte identification and 
measurements 
We analyzed three regions comprising ~100 adipocytes in three H&E BC slides using 
HALO®, Adiposoft and AdipoCount (Fig. 1 and Supplementary Fig. 1-3). We first compared the 
three software with regard to adipocyte identification. We obtained a high specificity and a 
high sensitivity with HALO® for all the tested slides (Table 1). In contrast, AdipoCount had a 
high number of false positives resulting in a low specificity in recognizing CAAs. This software 
would therefore require a post-processing step to eliminate the objects that are improperly 
recognized as adipocytes. Adiposoft was characterized by a high number of false negatives, 
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since it failed to detect adipocytes when the quality of the H&E stain was not optimal 
(Supplementary Fig. 2E). This software would therefore require a pre-processing for each slide 
to adjust the image threshold.  
We then compared the areas and the diameters computed by the three software 
considering 20 individual adipocytes per slide. The results were reported in Bland–Altman 
plots depicting the difference between two software’s measurements against their mean. 
There was no major constant (intercept) or proportional (slope) drift between the three 
methods, as shown in the Passing–Bablok regression analysis (Fig. 1B,C,F). The concordance 
correlation coefficients confirmed a substantial concordance between the three methods for 
both area and diameter (Fig. 1B,C,F, Supplementary Fig. 1B,C,F; Supplementary Fig. 2B,C,F).  
To conclude, we opted for HALO® for downstream analyses because of its higher 
specificity and sensitivity in adipocyte recognition and the ease of use, not needing pre- or 





Figure 4. Comparison of adipocytes measurements by AdipoCount, Adiposoft and HALO. 
Representative image of a test slide analyzed with AdipoCount (A), Adiposoft (E) and HALO® (I). Bland–Altman plots (D, G, H) showing 
software agreement between two software using area measurement of twenty adipocytes. For each comparison, the averaged area of each 
adipocyte calculated by software (x axis) is plotted against the difference between the two area measurements of the same adipocyte. The 
solid and dashed horizontal lines represent the overall geometric mean of the differences and the 95% confidence intervals respectively. 
Passing–Bablok regressions of adipocyte areas of AdipoCount vs Adiposoft (B), AdipoCount vs HALO® (C), and Adiposoft vs HALO® (F) are 
shown. Each comparison is represented by a scatter diagram where the regression line and 95% pointwise confidence bands are 
superimposed with the identity line (dashed line). The intercept and slope are reported with their 95% confidence intervals (CI). CCC: 











































































































Table 3. Comparison of the counting results of AdipoCount, Adiposoft and HALO®. 
Manual count is the reference. FN: False negative, FP: false positive, TP: true positive, TN: true negative. 
 
Intra-mammary heterogeneity of CAAs and distant adipocytes 
We aimed to investigate whether intra-mammary heterogeneity in the size distribution 
of distant adipocytes and CAAs should be taken into consideration or not. Specifically, we 
aimed at assessing whether a single region of at least 500 adipocytes would provide a good 
representation of the adipocytes (distant or CAAs) present in the tissue. To this end, we 
analyzed ~ 500 distant adipocytes and ~ 500 CAAs in each single digital slide taken from ten 
BC samples. Intra-patient variability in adipocyte size was low for both CAAs and distant 
adipocytes, as illustrated in Fig. 2 for one of the patients. We further generated the cumulative 
distribution of the adipocyte areas and diameters for the ten patients and represented the 
intra-mammary heterogeneity for both the CAAs and distant adipocytes by displaying the 
range of adipocyte measurements for each quartile (Supplementary Fig. 4 and 5). Altogether, 
the cumulative distribution of CAAs and distant adipocytes area in each of the 10 patients 
revealed small intra-patient variability in each group, which led us to further consider a single 
region of at least 500 adipocytes (CAAs or distant) to estimate the distribution of the 






Figure 5. Intra-mammary heterogeneity of distant and cancer-associated adipocytes. 
Violin plots and boxplots of adipocytes diameter and adipocytes area of three regions close to the tumor (CAAs, blue) and 
three regions distant (distant adipocytes, red) in three slides taken from one patient (D, H). Each scanned slide has an 





Comparison of distant adipocytes and CAAs using digital pathology 
We compared the diameter and area of CAAs with those from the distant adipocytes 
(Fig. 3 and Supplementary Table 1 for detailed comparisons at the patient-level). Across all 
evaluated tumors, the mean diameter was 50.0 μm for CAAs and 77.3 μm for distant 
adipocytes and the median diameter was 46.7 μm and 76.1 μm, respectively (unpaired 
Wilcoxon test, p < 0.001). The mean area was 2311.8 µm2 for CAAs and 5537.4 μm2 for distant 
adipocytes and the median area was 1881.3 μm2 and 4853.0 μm2, respectively (unpaired 
Wilcoxon test, p < 0.001). Furthermore, comparing CAAs to distant adipocytes within each 
tumor, we observed that CAAs had smaller areas (median fold-change: 2.62, IQR: 2.15 – 2.65) 
and diameters (median fold-change: 1.64, IQR: 1.50 – 1.67) as compared to distant adipocytes 
(paired Wilcoxon test, p = 0.002 and p = 0.002, respectively). Of interest, the reduction in 
adipocytes diameter and area between distant and CAAs is consistent at each quantile in all 
samples (paired Wilcoxon tests, p = 0.002 and p = 0.002, respectively) (Fig. 3). These results 
therefore highlight the consistent reduction in size between distant adipocytes and CAAs, 





Figure 6. Plots of the size difference between distant and cancer-associated adipocytes. 
Parallel plots (A, B, C) with associated boxplots (D) show the variations of adipocytes diameters between distant and cancer-
associated adipocytes at 25th percentile (A), 50th percentile (B), and 75th percentile (C). Below, parallel plots (E, F, G) with 
associated boxplots (H) show the variations of adipocyte areas between distant and CAAs at 25th percentile (E), 50th 
percentile (F), and 75th percentile (G). Each line and each dot correspond to a patient and are colored according to ascending 
BMI. For each percentile, the p-value from the paired Wilcoxon tests was 0.002 for both diameters and areas. CAAs: cancer-
associated adipocytes. 
 
Association between CAAs and distant adipocytes measurements and BMI 
The distributions of adipocyte measurements for the ten patients according to the BMI 
are illustrated in Figure 4. We observed a correlation between BMI as a categorical variable 
(lean, overweight or obese) and adipocyte measurements with regard to area (Kendall’s tau = 
0.80, p = 0.004 for CAAs, and Kendall’s tau = 0.65, p = 0.021, for distant adipocytes) and 
diameter (Kendall’s tau = 0.75 p = 0.007, Kendall’s tau = 0.59, p = 0.035, respectively). The 
correlation was further confirmed when considering BMI as a continuous variable, both with 
regard to area of CAAs and distant adipocytes (rho = 0.89 p = 0.001; rho = 0.71 p= 0.027, 





Figure 7. Distribution of adipocyte sizes in ten patients according to BMI. 
Violin plots (A, B) including boxplot that represents the 25th, median and 75th percentiles of diameters for CAAs (A) and 
distant adipocytes (B) in ten patients ordered by ascending BMI. Violin plots (C, D) including boxplot that represents the 25th, 
median and 75th percentiles of areas for CAAs (C) and distant adipocytes (D) in ten patients ordered by ascending BMI. The 
violin plots outlines illustrate kernel probability density, i.e. the width of the colored area represents the proportion of the 
adipocyte diameters (A, B) and adipocytes areas (C, D). The same color code as in Fig. 3 has been used. 
Discussion 
So far, digital pathology has not yet been applied standardly to measure the distant 
adipocytes and CAAs in H&E samples from BC patients. Here, we compared different software 
to detect and measure mammary adipocytes. In addition, we defined criteria to distinguish 
CAAs from distant adipocytes in breast tumor samples. All the software we tested had a good 
agreement in the measurement of both the area and the diameter of the adipocytes. 
However, regarding the adipocyte identification, the highest sensitivity and specificity were 
reached by HALO®, while these were unsatisfactory for the other two software. AdipoCount 
further does not provide the diameter of the cells and that does not allow setting a lower 
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range for the area in order to avoid false positives, such as interstitial optical empty spaces. 
Adiposoft failed to identify adipocytes when tested on slides with a lower staining quality of 
the fat tissue. On the basis of these results, we conducted our subsequent analyses with 
HALO®. In addition, we observed that ~500 adipocytes (distant or CAAs) provide a realistic 
representation of the adipocyte measurements given the minimal intra-mammary variability. 
We acknowledge that there might be additional free or commercial digital pathology software 
able to identify and measure adipocytes, such as QuPath[131] or Visiopharm® for example, 
however these were not considered in this study since they did not have already existing 
applications for identifying and measuring adipocytes. 
Delipidation and the accompanying size reduction of CAAs as compared to distant 
adipocytes are key features of CAAs[113,142]. However, to the best of our knowledge, the size 
reduction has never been quantified and evaluated across several breast tumors. Our results 
clearly show that CAAs are smaller than distant adipocytes, with a median 1.6-fold decrease 
in diameter and a median 2.6-fold decrease in area when comparing CAAs and distant 
adipocytes from the same tumor. While this will need to be investigated in larger series, we 
hypothesize that the magnitude of the decrease in size between distant and CAAs could 
potentially reflect the strength of the interaction between cancer cells and adipocytes. The 
reduction of size could be a surrogate of lipid use as energy source by cancer cells[143]. It still 
has to be investigated whether it is associated with specific clinical, pathological or treatment 
characteristics which is ongoing. 
Finally, we investigated the association between BMI and the size of the CAAs and 
distant adipocytes. It has been demonstrated that the MAT expands preferentially through 
the hypertrophy than through the hyperplasia of the adipocytes[144,145]. So far, the studies 
that investigated the association between BMI and the size of the adipocytes in the MAT of 
BC patients focused on distant adipocytes only and based their measurements on a limited 
number of adipocytes[58]. While it is known that BMI might not be the best surrogate marker 
for the adiposity of a patient, it remains the most commonly used measurement in clinical 
practice. The hypothesis is that hypertrophy of adipocytes may be a more reliable indicator of 
a patient’s adiposity determining an unhealthy MAT as shown in previous studies[58]. We 
found a significant correlation between BMI and the diameter and area of both CAAs and 
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distant adipocytes, with patients with a higher BMI having not only larger distant adipocytes, 
as previously demonstrated[76], but also larger CAAs.  
Conclusions 
While we reckon that this study is based on a relatively small number of samples and 
patients, this is, to the best of our knowledge, the first to investigate both CAAs and distant 
adipocytes by digital software analysis in BC samples. Our study sets the basis for the 
standardized analysis of larger cohorts of BC patients, providing a more accurate estimation 
of mammary adiposity. Of interest, this analysis could further be extended to other cancer 
types that grow in close contact with the adipose tissue, such as soft tissue tumors, renal 





Statistical analysis  
A sample size analysis and a power calculation were performed: 1a) to determine the sample 
size to assess sensitivity and specificity of the software for recognizing and counting the 
adipocytes, 1b) to determine the number of adipocytes for the software comparison regarding 
areas and diameters, and, 2) to compare the distribution of the diameter and area of distant 
and CAAs according to their means. Concerning the sensitivity and specificity analyses a 
sample size of 150 objects, of which 100 are adipocytes lead to a power of 90% and 70% with 
a 0.05 significance level (two-sided) to show a 15% difference in sensitivity and specificity 
respectively given a proportion of discordant pairs of 20% according to the tests for paired 
sensitivities PASS procedure. For the comparison of the software regarding adipocyte 
diameter and area, measuring 20 adipocytes results in 84% power with a 0.05 significance 
level (one-sided) according to the Lin’s concordance correlation coefficient PASS procedure. 
For point 2, a sample size of 500 adipocytes in each of the two categories distant and CAAs 
should achieve a power of 90% at a level of significance of 0.05 (two-sided) to detect a 
difference in means of 0.1 given a standard deviation of 0.4 and 0.5 for log transformed area 
distribution in CAAs and distant adipocytes respectively according to the two-sample T-tests 
allowing unequal variance PASS procedure. In term of variance, the same sample size should 
achieve a power of 90% at level of significance of 0.05 in a F test to detect a ratio of 0.74 from 
CAAs to distant adipocytes when setting their variances to 0.4 and 0.5 respectively in the tests 






Figure 8. Comparison of adipocytes measurements by AdipoCount, Adiposoft and HALO®. 
Representative image of a test slide analyzed with AdipoCount (A), Adiposoft (E) and HALO® (I). Bland–Altman plots (D,G,H) 
showing software agreement between two software using area measurement of twenty adipocytes. For each comparison, 
the averaged area of each adipocyte calculated by software (x axis) is plotted against the difference between the two area 
measurements of the same adipocyte. The solid and dashed horizontal lines represent the overall geometric mean of the 
differences and the 95% confidence intervals respectively. Passing–Bablok regression of adipocyte areas of AdipoCount vs 
Adiposoft (B), AdipoCount vs HALO® (C), and Adiposoft vs HALO® (F) are shown. Each comparison is represented by a scatter 
diagram where the regression line and 95% pointwise confidence bands are superimposed with the identity line (dashed line). 





Figure 9. Comparison of adipocytes measurements by AdipoCount, Adiposoft and HALO®. 
Representative image of a test slide analyzed with AdipoCount (A), Adiposoft (E) and HALO® (I). Bland–Altman plots (D,G,H) 
showing software agreement between two software using area measurement of twenty adipocytes. For each comparison, 
the averaged area of each adipocyte calculated by software (x axis) is plotted against the difference between the two area 
measurements of the same adipocyte. The solid and dashed horizontal lines represent the overall geometric mean of the 
differences and the 95% confidence intervals respectively. Passing–Bablok regression of adipocyte areas of AdipoCount vs 
Adiposoft (B), AdipoCount vs HALO® (C), and Adiposoft vs HALO® (F) are shown. Each comparison is represented by a scatter 
diagram where the regression line and 95% pointwise confidence bands are superimposed with the identity line (dashed line). 





Figure 10. Comparison of adipocytes measurements by Adiposoft and HALO®. 
Passing–Bablok regression (A,B,C) of adipocyte diameters of Adiposoft vs HALO® of three test slides. Each comparison is 
represented by a scatter diagram where the regression line and 95% pointwise confidence bands are superimposed with the 
identity line (dashed line). The intercept and slope are reported with their 95% confidence intervals (CI). CCC: concordance 
correlation coefficient. Bland–Altman plots (D,E,F) showing software agreement between two software using diameter 
measurement of twenty adipocytes. For each comparison, the averaged diameter of each adipocyte calculated by software 
(x axis) is plotted against the difference between the two diameter measurements of the same adipocyte. The solid and 






Figure 11. Cumulative distribution of CAAs and distant adipocytes area. 
Each panel is dedicated to a patient, each curve represents an area of 500 adipocytes. Blue and red curves depict the 
cumulative distributions of area for CAAs and distant adipocytes respectively. The horizontal dashed lines represent the 25th, 
median and 75th percentiles from bottom to top respectively. Values provided on each dashed line provide the maximal 





Figure 12. Cumulative distribution of CAAs and distant adipocytes diameter. 
Each panel is dedicated to a patient, each curve represents an area of 500 adipocytes. Blue and red curves depict the 
cumulative distributions of diameter for CAAs and distant adipocytes respectively. The horizontal dashed lines represent the 
25th, median and 75th percentiles from bottom to top respectively. Values provided on each dashed line provide the maximal 





The inflammatory TME of BC is an important driving factor for the progression of the disease 
and may become a potential target for new and personalized treatments, especially in 
overweight and obese patients. Most of the theoretical basis for studying the role of 
adipocytes originates from epidemiological and clinical studies that documented worse 
outcomes in obese BC patients, with potential differences according to the molecular subtype 
of tumor and the menopausal status of the patient[30,32]. Although adipocytes may be one 
of the mediator between obesity and BC, the specific mechanisms still remain to be 
elucidated[117]. It has already been described that mammary adipocytes tend to be larger 
(hypertrophied) in obese as compared to lean patients. Dirat and colleagues also reported the 
plasticity of these cells, by describing for the first time the existence of the so-called CAAs in 
human cancers[113]. However, so far, there are no defined criteria and methods to quantify 
mammary adipocytes and CAAs in BC samples. For this reason, we conducted our research on 
a small group of post-menopausal ER+ BC women, with the main aim of evaluating the 
feasibility of using digital pathology to measure adipocytes and CAAs in BC. The analysis of 
these ten patients sets the standard for digital analysis of adipocytes in all our future studies. 
At the time of writing, we are concluding the analysis on the entire cohort from which these 
ten patients are taken, and we will submit the results for publication soon. 
The results of the present research are threefold. First, we identified the best software to 
identify and measure adipocytes in the MAT of BC. We observed that one of the most 
important limitation was the low quality of the H&E staining or the damaged AT as previously 
described. For that reason, to have an accurate representation of AT and minimize bias, it is 
important to exclude slides with damaged AT. In addition, we identified a number of 500 
adipocytes as sufficient number to have a good representation of the adiposity of a patient 
minimizing the intra-patient and intra-slide heterogeneity. We established important criteria 
for the recognition of CAAs, defining them as located in the first 3-5 lines from the IF and no 
more than 2 mm deeper in the tumor tissue. We consider that our criteria have a potential 
impact on other research projects. Furthermore, no previous studies directly measured CAAs 
at the IF of BC through image analysis software. To our knowledge, we are the first to perform 
this type of analysis in BC comparing distant and CAAs. Second, we demonstrated that CAAs 
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are smaller than distant adipocytes, reflecting the delipidation process undergone by CAAs. 
Third, BMI of the patient was associated with the size of distant adipocytes and CAAs. Of 
interest, we observed that adipocyte distributions were characterized by a certain overlap 
between them, especially in the same BMI category, supporting our concept that BMI might 
not be a reliable estimator of fat cells properties. Moreover, we did not find any difference in 
adipocytes size according to the histology (ductal vs lobular, results not shown), possibly also 
due to the small number of the samples that were evaluated. Therefore, open questions 
remain, such as whether obesity amplifies the metabolic crosstalk between CAAs tumor cells 
in all BC subtypes and histological subtypes and what the determinants are of this adipocytes 
size reduction.  
There are some limitations in this study that could be addressed in future research. First, the 
limited small sample size that prevented us to investigate additional associations with clinical 
and pathological variables. However, we are currently exploring these association on the 
entire cohort and the results will be presented soon. Second, we did not perform any 
immunohistochemical or histochemical analysis on our samples. Hence, we identified CAAs 
exclusively according to morphological and topographic criteria. Third, our cohort was 
composed of post-menopausal ER+ BC women treated with neoadjuvant therapy with 
letrozole. Therefore, we cannot exclude an interaction of letrozole with adipocytes in 
determining a change in their size. In addition, we also cannot exclude an interaction of other 
types of treatment used by the patients with adipocytes size. The analysis of the pre-
treatment biopsies was not possible due to small quantity of AT presented on those samples. 
Also, the intra-tumoral population of adipocytes was not considered because it was not 
present in all the samples, but we will further explore it in future studies. In order to have 
sufficient MAT for this type of analysis, future studies on mammary adipocytes could benefit 
from adaptations in the surgical breast pathology pipeline. Finally, we recognize the 
exploratory nature of this work; however, our findings will be the basis to extend the 
application of digital pathology to measure adipocytes on large clinical trials. 
Conclusions and Future Perspectives  
 
In parallel to the present research, I took part in another work where we assessed breast 
adipose features using digital pathology in a case-control study nested population-based 
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ductal carcinoma in situ (DCIS) cohort[111]. We showed that women with DCIS and large 
adipocytes size might have an increased risk of subsequent ipsilateral invasive BC compared 
to women with DCIS and smaller adipocytes. Although BMI was missing for several patients, 
this study demonstrated that adipocyte size associated to the presence of CLS, could be a 
reliable indicator of mammary adiposity and MAT inflammation. This finding might also be 
relevant for the group of metabolically obese normal-weight women in which BMI is not able 
to discriminate the inflamed MAT[78]. Taken together, these findings have important 
implications showing that an altered AT micro-environment preexisting to the tumor might 
already be an active contributor to BC initiation adding insights to improve the follow-up of 
women with DCIS. 
Another important aspect that should be considered for the future is our currently poor 
understanding of adipocyte heterogeneity and functional specialization. A few studies, mostly 
in mice, through single-cell genomics analyzed normal AT identifying an homogenous cell 
population of ASCs[146] whereas instead there seems to be different subpopulations of pre-
adipocytes and mature adipocytes[147–149]. Currently, none of the large-scale molecular 
characterization studies of BC have considered patient’s adiposity. To overcome this lack of 
knowledge, our research group have recently started a clinical trial (National Library of 
Medicine [NLM], NCT04200768)[150] with the aims, using single-nuclei and lipidomics data, 
to characterize the micro- and macroenvironment of BC according to patient’s adiposity in 
different histological and molecular subtypes. Furthermore, we will use multi-level adiposity 
measurements among which the measurement of adipocytes size through digital pathology 
that it was validate with the work described in this thesis. Of interest, we will conduct our 
analysis also on normal mammary tissue samples as controls in order to dissect the 
transcriptome of mammary adipocytes (progenitors, mature and CAAs) also according to the 
presence or not of cancer. 
Another study has been recently started from our research group (National Library of 
Medicine [NLM], NCT04531696)[151]. This study consists on extensive post-mortem multi-
level and multi-region sample analysis of women who died for metastatic BC in order to 
unravel BC evolution, biology, heterogeneity, and treatment resistance. One of the novelty of 
this study is that digital pathology and molecular analyses of adipocyte will be performed on 
the different metastatic lesions collected during the autopsy. The initial pilot phase with the 
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analysis of the first two patients is completed and we were able to perform CAAs analysis on 
various metastatic sites.  
Finally, we believe that our analysis can be expanded to the AT TME of other cancer types. For 
example, several studies described bone marrow adipose tissue (BMAT) as a niche for tumor 
cells, for both solid and hematologic malignancies[152,153]. Bones are one of the favorite site 
of metastases in HR+ BC, therefore it will be important to study how adipocytes of BMAT 
contributes to creating a unique metastatic niche[154]. 
To conclude, while the work presented here aims to characterize mammary adipocytes in BC 
patients using digital pathology, future studies with larger number of patients combining this 
type of analysis with multi-omics approaches are necessary to provide further insights in the 
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